share_log

騰盛博藥-B:(1)執行董事辭任 ; (2)委任執行董事 ; (3)戰略委員會組成變動 ; 及(4)委任中國研發主管及大中華區總經理

BRII-B: (1) RESIGNATION OF EXECUTIVE DIRECTOR; (2) APPOINTMENT OF EXECUTIVE DIRECTOR; (3) CHANGE IN COMPOSITION OF STRATEGY COMMITTEE; AND (4) APPOINTMENTS OF HEAD OF CHINA R&D AND GENERAL MANAGER, GREATER CHINA

Sep 2, 2022 07:01
Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more